Drug for Rare Genetic Disease Gets FDA Approval

Angiodema Drug Approved By FDA
HealthDay News


THURSDAY, July 17, 2014 (HealthDay News) -- Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal tract or airways.

The disease, affecting as many as 10,000 people in the United States, is caused by the body's inability to produce enough of a plasma protein called C1-esterase inhibitor. The remedy is produced from the milk of genetically-modified rabbits, the FDA said Thursday in a news release.

Ruconest was evaluated in a clinical study of 44 adults and adolescents with hereditary angioedema. The most common side effects recorded were headache, nausea and diarrhea.

Ruconest is manufactured by the Netherlands-based Pharming Group NV, and will be distributed by a subsidiary of Salix Pharmaceuticals, based in Raleigh, NC.

Copyright © 2014 HealthDay. All rights reserved.

Published: July 2014

ADVERTISEMENT

What You Need to Know About Glaucoma: Q&A With Dr. Marlene R. Moster

What you can't see — the invisible disease that can leave you blind

Eye Conditions & Disorders

Your Corner Pharmacy – Joining the Front Lines of the Covid-19 Fight

Pharmacists will play a central role in the Biden administration's push to get America vaccinated against COVID-19

Prevention & Screenings

¿Necesita Ver a un Cardio-Oncólogo?

Los tratamientos que salvan vidas pueden aumentar el riesgo de enfermedades cardíacas. Un cardio-oncólogo puede ayudar a mantener su corazón sano mientras lucha contra el cáncer.

Created With Support